Industry Insights

  1. Finding Solid Ground In New Markets

    In the recent Economist Intelligence Unit survey on biopharma’s present and future, biopharma industry leaders expressed excitement and some uncertainty about the emerging markets of the Middle East and Africa. Respondents saw great opportunity in these regions, but also cited potential risks in relation to regulatory questions and stability issues. We spoke with Bert de Vet, Head of Commercial EMEA Process Solutions at MilliporeSigma, about his take on growth in the region and some of the ways companies entering these regions can mitigate risk.

  2. Why Data Liquidity Is Your Company's New Business Objective

    How to merge ECM, BPM and archiving strategies so data and analytics power the content lifecycle.

  3. Will Single-Use Standardization Take End User & Supplier Relationship To The Next Level?

    To continue the evolution of single-use technology (SUT) in biopharma, one area that must be secured is SUT supply chain reliability. Without this, a larger scale adoption of SUT may continue to be delayed as biopharmaceutical manufacturers must have access to a reliable supply chain that allows us to successfully deliver product to our customers.

  4. Single-Use Tech And Sustainability: Quantifying The Environmental Impact

    In the shift to single-use technology, there is both an opportunity and an obligation to understand the sustainability impacts of this development.

  5. 3 Regulatory Guidelines For Navigating China’s Drug Delivery And Medical Device Markets

    Global spending on healthcare medicines is expected to reach $1.3 trillion by end of year 2018. While many of these medicines may be developed in the traditional dosage forms, companies are increasingly developing more and more drug delivery devices, in order to deliver patient convenience, more effective routes of administration through targeted therapies, and value to the global payors. As the world’s second largest medical device market, China offers a significant opportunity for drug delivery companies to expand their global footprint in Asia.

  6. Understanding Analytical Method Validation

    During my years in analytical development science at biotechnology companies including Celera and Genentech, it became routine to develop analytical assays to test products such as proteins, monoclonal antibodies, recombinant protective antigen, DNA, RNA, etc. These tests were predominantly developed on high performance liquid chromatography (HPLC), mass spectroscopy (MS), DNA sequencers, and other state-of-the-art techniques.

  7. 5 Questions To Answer Before Starting Your CMO Search

    Finding the CMO that is right for your company and project can be a daunting task, particularly if this is your first time outsourcing. Some companies, especially those with limited experience in the biopharmaceutical industry, may find themselves unprepared when it comes to beginning the search.

  8. Useful Tips For Fab Protein Purification

    While protein purification is a well-established, conventional and highly trusted discipline, the approaches it employs can be as diverse as its targets. This makes a lot of sense as proteins come in many different sizes, structures and possess unique binding affinities and biological activities. As such, it’s not surprising that specific proteins require purification strategies tailored to their own unique physico-chemical properties.

  9. Rapid Single–Step Purification Of Proteins From Whey

    Whey proteins play a vital role in the formulation of food supplements because of numerous desirable nutritional and functional properties. The objective of this study was to develop a separation process to fractionate usable proteins from whey. First, total whey protein isolate (WPI) was purified because of its high-end functional advantages, as evidenced by a demand from nutrition and health segments. Second, ALA and BLG were purified because of their value in infant formula and confections, respectively.

  10. Evolution Of Biologic Pipelines Calls For Next-Generation Expression Systems

    Today’s mAb competition focuses on unmet therapeutic needs and biological mechanisms that have not yet been explored. As a result of this evolution, the purification of biologics is becoming increasingly challenging. This article discusses Lonza’s XS™ expression platform, which addresses the need for next-generation expression systems.